10 completed. 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
Follow Toxemia: new trials by email Literature Review of Toxemia trials Research Report on Toxemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS Allocetra-OTS - Organ Dysfunction Syndrome Sepsis | Phase 1 | Completed | Enlivex Therapeutics Ltd. | 10 | 2019-01-27 | 2020-05-19 |
| PK/PD of EA-230 During Endotoxemia EA-230, Endotoxin, Placebo - Endotoxemia, Systemic Inflammatory Response | Phase 1 | Completed | Radboud University Medical Center | 60 | 2015-02-01 | 2016-06-23 |
| Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections CAZ-AVI - Systemic Infections | Phase 1 | Completed | Pfizer | 35 | 2013-07-01 | 2017-09-06 |
| Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio) Antibiotic - Systemic Infection | Phase 1 | Completed | Phillip Brian Smith | 63 | 2013-01-01 | 2023-07-27 |
| A Possible Therapeutic Role for Adenosine During Inflammation AMPD1 polymorphism, Caffeine infusion, placebo - Endotoxemia | Phase 1 | Completed | Radboud University Medical Center | 33 | 2007-08-01 | 2009-10-01 |
| Anti-Inflammatory Effect of Statins in the Human Endotoxin Model LPS 2ng/kg intravenous bolus, Simvastatin 80mg; administered daily p.o. over 5 days, Rosuvastatin 40mg; administered daily p.o. over 5 days - Endotoxemia | Phase 1 | Completed | Medical University of Vienna | 6 | 2006-03-01 | 2007-01-05 |
| Ethnic Differences in the Inflammatory Response in Systemic Inflammation LPS - Endotoxemia | Phase 1 | Completed | Medical University of Vienna | 32 | 2006-01-01 | 2006-09-13 |
| Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans repeated injections of endotoxin during 5 days - Endotoxemia | Phase 1 | Completed | Radboud University Medical Center | 16 | 2005-10-01 | 2008-04-15 |
| Effect of Selective iNOS Inhibition During Human Endotoxemia Aminoguanidine, endotoxin - Endotoxemia | Phase 1 | Completed | Radboud University Medical Center | 7 | 2005-01-01 | 2008-04-15 |
| Blockade of Vascular Potassium Channels During Human Endotoxemia endotoxin, Potassium channel blockers: TEA, Quinin, Tolbutamide, L-NMMA - Endotoxemia | Phase 1 | Completed | Radboud University Medical Center | 36 | 2003-01-01 | 2008-10-17 |
Endotoxemia (7) · Inflammation (1)
Infections (10) · Bacteremia (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Sepsis (7) · Systemic Inflammatory Response Syndrome (7) · Inflammation (6)
Endotoxins (3) · Lipopolysaccharides (2) · Anti-Bacterial Agents (1) · Tolbutamide (1) · alanyl-glutaminyl-glycyl-valine (1) · omega-N-Methylarginine (1) · pimagedine (1)
Radboud University Medical Center (5) · Medical University of Vienna (2) · Enlivex Therapeutics Ltd. (1) · Pfizer (1) · Phillip Brian Smith (1)
Netherlands (4) · Austria (2) · United States (2) · Israel (1)
Christa Firbas, MD (1) · Dror Mevorach, Prof (1) · John Bradley, MD (1) · Michael Wolzt, MD (1) · P Pickkers, MD, Prof. (1) · Paul Newell, MBBS, MRCP (1) · Peter Pickkers, MD PhD (1) · Peter Pickkers, MD, PhD (1) · Peter Pickkers, MD,PhD (1) · Peter Pickkers, PhD (1) · Philip B Smith, MD (1)
PMID 16864730, PMID 18433844, PMID 20444270, PMID 21211004, PMID 26926644, PMID 27503642, PMID 28137820, PMID 30710387, PMID 30910891, PMID 30919998, PMID 34659208, PMID 34687548